Luminex Co. (NASDAQ:LMNX) announced a quarterly dividend on Friday, May 18th, RTT News reports. Shareholders of record on Friday, June 22nd will be given a dividend of 0.06 per share by the medical instruments supplier on Friday, July 13th. This represents a $0.24 dividend on an annualized basis and a yield of 0.88%.
Luminex opened at $27.20 on Friday, according to Marketbeat. Luminex has a 12-month low of $18.62 and a 12-month high of $27.24. The firm has a market cap of $1.17 billion, a PE ratio of 29.89, a PEG ratio of 2.17 and a beta of 0.11.
Get Luminex alerts:Luminex (NASDAQ:LMNX) last posted its quarterly earnings results on Monday, May 7th. The medical instruments supplier reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.08. Luminex had a return on equity of 8.07% and a net margin of 10.60%. The business had revenue of $82.60 million for the quarter, compared to the consensus estimate of $80.52 million. During the same quarter in the prior year, the company earned $0.28 EPS. The business’s revenue was up 6.2% compared to the same quarter last year. research analysts forecast that Luminex will post 0.75 earnings per share for the current fiscal year.
A number of research firms have recently issued reports on LMNX. BidaskClub raised Luminex from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 19th. BTIG Research set a $26.00 price target on Luminex and gave the stock a “buy” rating in a research report on Tuesday, May 8th. ValuEngine raised Luminex from a “hold” rating to a “buy” rating in a research report on Tuesday, May 8th. Deutsche Bank raised Luminex from a “sell” rating to a “hold” rating and set a $22.00 price target on the stock in a research report on Monday, May 7th. Finally, William Blair reissued a “market perform” rating on shares of Luminex in a research report on Tuesday, February 13th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $24.00.
In related news, SVP Todd C. Bennett sold 2,235 shares of the firm’s stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $25.95, for a total transaction of $57,998.25. Following the sale, the senior vice president now owns 21,309 shares of the company’s stock, valued at $552,968.55. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.40% of the stock is owned by company insiders.
About Luminex
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.
No comments:
Post a Comment